XML 20 R10.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2013

Note 4. Inventories:

Inventories at June 30, 2013 and December 31, 2012 were as follows:


	June 30, 2013									December 31, 2012
	Approved			Pending regulatory approval			Inventory			Approved			Pending regulatory approval		Inventory
Finished goods	$	51,343		$	1,747		$	53,090		$	46,410		$	1,437	$	47,847
Raw materials		4,618			—			4,618			1,280			—		1,280
Inventory reserve		(1,525	)		(1,437	)		(2,962	)		(2,021	)		—		(2,021	)

	$	54,436		$	310		$	54,746		$	45,669		$	1,437	$	47,106

During the second quarter, we recorded a $1,437 reserve for certain inventory that had been manufactured in advance of FDA approval, as we no longer believe the product will be launched prior to the expiry of the previously manufactured lots.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details